3 stories mentioning NVCR
Every FINWIRES story that references NVCR, newest first.
Frank X Leonard, Chief Executive Officer, on June 04, 2026, sold 34,273 shares in Novocure (NVCR) for $614,635. Following the Form 4 filing with the SEC, Leonard has control over a total of 459,520 ordinary shares of the company, with 459,520 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1645113/000182287926000004/xslF345X05/primarydocument.xml
Health care stocks rose Thursday afternoon with the NYSE Health Care Index climbing 2.5% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.3%.The iShares Biotechnology ETF (IBB) advanced 2%.In corporate news, Eli Lilly (LLY) raised its full-year outlook and reported Q1 results above market estimates as sales of Mounjaro more than doubled. Lilly shares jumped 10%.The US Food and Drug Administration is proposing to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances. Eli Lilly makes tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Novo Nordisk (NVO) makes semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management. Novo shares rose 5.0%.NovoCure (NVCR) shares surged 28% after the company posted Q1 results.
NovoCure (NVCR) shares were up more than 24% in Thursday trading after the company posted its Q1 financial results.The pharmaceutical company reported early Thursday a Q1 net loss of $0.62 per diluted share, widening from a loss of $0.31 a year earlier.Analysts polled by FactSet expected a loss of $0.51.Net revenue for the quarter ended March 31 was $174.1 million, up from $155 million a year earlier.Analysts surveyed by FactSet expected $167.8 million.The company said it now expects 2026 total net revenue of $690 million to $710 million, compared with its prior guidance of between $675 million and $705 million. Analysts polled by FactSet expect $694.7 million.Price: $14.81, Change: $+2.88, Percent Change: +24.14%